The dual recognition highlights the company's end-to-end service model, which integrates discovery, development, and manufacturing. Dr. Jimmy Li, CEO of WuXi XDC, credited the achievement to the firm's focus on technological innovation and global collaboration. The company currently supports a diverse pipeline, having completed research on more than 22,000 ADC and XDC molecules to date.

Operational efficiency remains a core pillar of the business, with the firm enabling clients to move from DNA to preclinical candidate within 10 months and to IND application within 15 months. This capacity is bolstered by proprietary platforms such as WuXiDARx and the WuXiTecan-2 linker technology. The company's reach expanded significantly in August 2026 with the successful GMP release of its first overseas manufacturing site in Singapore, complementing its existing network across China.

As of June 30, 2026, the company serves a client base of over 810 partners, including 15 of the top 20 global pharmaceutical firms by revenue. With 328 active iCMC projects—51 of which were signed in the first half of the year—the organization continues to scale its workforce, which now includes over 3,600 employees.